Cardio Diagnostics Holdings (CDIO) Profit After Tax (2021 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Profit After Tax of -$1.8 million for Q1 2026, down 22.03% sequentially from -$1.5 million in Q4 2025, and down 9.36% YoY from -$2.0 million in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Profit After Tax (2021 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Profit After Tax for 6 years, with the latest figure at -$1.8 million in Q1 2026.
- Quarterly Profit After Tax fell 9.36% year-over-year to -$1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.7 million (down 13.6% YoY) and the FY2025 annual result came in at -$6.5 million, up 22.49% from the prior year.
- Profit After Tax declined to -$1.8 million in Q1 2026 per CDIO's latest filing, from -$1.5 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$290055.0 in Q1 2022 and troughed at -$4.2 million in Q1 2024.
- A 5-year average of -$1.7 million and a median of -$1.5 million in 2024 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2022 and 2024: Profit After Tax plunged 211990.18% in 2022, then jumped 67.98% in 2024.
- Over 5 years, Profit After Tax stood at -$2.4 million in 2022, then surged by 41.59% to -$1.4 million in 2023, then fell by 9.39% to -$1.5 million in 2024, then rose by 3.55% to -$1.5 million in 2025, then slipped by 22.03% to -$1.8 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$1.8 million, -$1.5 million, and -$1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Cardio Diagnostics Holdings | 6.05 Mn | 460,682.10 | - | -1.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.50 Mn |
| Mar 31, 2026 | -1.79 Mn |
| Dec 31, 2025 | -1.47 Mn |
| Sep 30, 2025 | -1.71 Mn |
| Jun 30, 2025 | -1.68 Mn |
| Mar 31, 2025 | -1.64 Mn |
| Dec 31, 2024 | -1.52 Mn |
| Sep 30, 2024 | -1.41 Mn |
| Jun 30, 2024 | -1.29 Mn |
| Mar 31, 2024 | -4.16 Mn |
| Dec 31, 2023 | -1.39 Mn |
| Sep 30, 2023 | -1.93 Mn |
| Jun 30, 2023 | -4.02 Mn |
| Mar 31, 2023 | -1.03 Mn |
| Dec 31, 2022 | -2.38 Mn |
| Sep 30, 2022 | -1.15 Mn |
| Jun 30, 2022 | -841,998.00 |
| Mar 31, 2022 | -290,055.00 |
| Dec 31, 2021 | -144,837.00 |
| Sep 30, 2021 | -721.00 |